The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American-based organisation, initiated in 1986 by Rick Doblin, which works to raise awareness and understanding of psychedelic substances.
MAPS works closely with government agencies worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), as it helps scientists to design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of controlled substances. MAPS has so far facilitated research into such worthy areas as;
- Alternative delivery systems for medical marijuana, such as vaporizers and water pipes.
- Ayahuasca for the treatment of drug addiction and PTSD
- Ibogaine for the treatment of opiate addiction
- LSD and psilocybin for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues
- MDMA for the treatment of posttraumatic stress disorder (PTSD)
- Medical marijuana for PTSD
In addition to sponsoring scientific research,
MAPS organises continuing medical education (CME) conferences, sponsors and presents lectures and seminars on the state of psychedelic and medical marijuana research, provides psychedelic harm reduction services through the Zendo Project at events such as music festivals and Burning Man, and publishes a triannual magazine-style publication, the MAPS Bulletin, with updates about its ongoing research efforts, legal struggles, and educational initiatives. MAPS also publishes books dealing with the science, history, and culture of psychedelic research and psychedelic therapy.”
The organisation’s ultimate aim is to establish a network of clinics where psychedelic and other treatments can be provided under the guidance of trained, licensed physicians and therapists.